Pre-made Otlertuzumab biosimilar ( di-scFv+Fc, anti-CD37 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-416
Anti-CD37 therapeutic antibody (Pre-made Otlertuzumab biosimilar,di-scFv+Fc) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Otlertuzumab (TRU-016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD37 therapeutic antibody (Pre-made Otlertuzumab biosimilar,di-scFv+Fc)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Trubion Pharmaceuticals;Aptevo Therapeutics|
|Conditions Discontinued||Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma|
|Development Tech||ADAPTIR Monospecific Platform|